News Release

SFDA Meeting For Phase II Clinical Trial In China

Date: November 19 , 2003

TSX Venture Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. (the "Company") is pleased to announce that it has been invited by the Chinese SFDA (State Food and Drug Administration) to discuss the clinical development of Tectin™ in chronic pain.

This meeting is to be held in Beijing on November 21, 2003 and will be led by our subsidiary, Nanning Maple Leaf Pharmaceuticals Co., Ltd.'s expert team. The lead investigator that conducted the Phase I clinical trial will give a full report on the findings during the meeting. In addition, Dr. Susan Lu from the Vancouver office will also present the interim results from our Phase IIa clinical trial in Canada.

The objective of the meeting is to discuss the Phase II study in non-malignant chronic pain. This study will be a comparative, multi-centre, randomized, double-blind, controlled study.

International Wex Technologies Inc., a publicly listed neuro-bioscience company (WXI), is focused on the development and commercialization of innovative drug products, primarily for pain management. The Company's lead compound, Tetrodotoxin, a sodium channel blocker, is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.

For additional information on our products, view the Company website at http://www.wextech.ca or call Gordon Stanley at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.